Economic burden of advanced lung cancer patients treated by gefitinib alone and combined with chemotherapy in two regions of China
CONCLUSIONS: The economic burden of lung cancer treatment mainly came from the cost of the drugs. Patients taking chemotherapy had significantly higher cost compared to patients using targeted therapy. The cost was generally higher for those with higher educational level, those with higher family income, and those living in an economically more developed city. Patients with NSCLC had higher cost compared to patients with SCLC.PMID:37855437 | DOI:10.1080/13696998.2023.2272536
Source: Journal of Medical Economics - Category: Health Management Authors: Kehong Yang Susan Hua Wenting Wei Congyan Yang Xinhai Zhu Shu Chuen Li Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | China Health | Economics | Education | Health Management | Lung Cancer | Non-Small Cell Lung Cancer | Small Cell Lung Cancer | Study